stockrowJazz Pharmaceuticals PLC
JAZZ Healthcare Biotechnology
Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024.
- Revenue
- +10.4%
- EPS
- −280.5%
- Free cash flow
- −60.4%
- Total debt
- +3.88%
Quarter to September 2026, against a year earlier
Follow JAZZ
Alert me
Jazz Pharmaceuticals PLC (JAZZ) EBITDA
Jazz Pharmaceuticals PLC's EBITDA for fiscal 2025 was $266.1M, down 80.7% from $1.4B in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.1B. Over the past ten years it has ranged from $266.1M (fiscal 2025) to $1.4B (fiscal 2024) — the current reading is the lowest in ten years. Jazz Pharmaceuticals PLC ranks 7th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $266.1M | (80.67%) |
| FY2024 | $1.4B | 13.10% |
| FY2023 | $1.2B | 115.85% |
| FY2022 | $563.9M | (21.97%) |
| FY2021 | $722.8M | 10.12% |
| FY2020 | $656.3M | (27.28%) |
| FY2019 | $902.5M | 3.08% |
| FY2018 | $875.5M | 20.93% |
| FY2017 | $724.0M | (0.49%) |
| FY2016 | $727.6M | 13.86% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | −$234.5M | — |
| Jun 2026 | $427.3M | (17.51%) |
| Mar 2026 | $518.0M | 19.42% |
| Dec 2025 | $433.8M | 83.95% |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC | $1.1B |
| EXEL Exelixis, Inc. compare | $1.0B |
| HALO Halozyme Therapeutics, Inc. compare | $719.2M |
| BMRN BioMarin Pharmaceutical Inc. compare | $374.0M |
| TECH Bio-Techne Corp compare | $349.2M |
| ASND Ascendis Pharma A/S compare | $321.3M |
| BBIO BridgeBio Pharma, Inc. compare | −$352.4M |
| KYMR Kymera Therapeutics, Inc. compare | −$405.5M |
| SMMT Summit Therapeutics PLC compare | −$872.8M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on JAZZ
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement